Indivior Pharmaceuticals (INDV) EBT (2024 - 2026)

Indivior Pharmaceuticals has reported EBT for 3 years, with the latest figure at $160.0 million in Q2 2026.

• On a quarterly basis, EBT rose 158.06% year-over-year to $160.0 million in Q2 2026; TTM through Jun 2026 was $393.0 million, a 107.94% increase from a year earlier, with the FY2025 full-year figure at $239.0 million, up 1095.0% from the prior year.
• EBT was $160.0 million for Q2 2026 at Indivior Pharmaceuticals, up from $115.0 million in the prior quarter.
• The five-year high for EBT was $160.0 million in Q2 2026, with the low at -$121.0 million in Q2 2024.
• Average EBT over 3 years is $53.4 million, with a median of $60.5 million recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: EBT fell 19.18% in 2025, then jumped 158.06% in 2026.
• Over 3 years, EBT stood at $38.0 million in 2024, then jumped by 113.16% to $81.0 million in 2025, then jumped by 97.53% to $160.0 million in 2026.
• The last three EBT figures came in at $160.0 million (Q2 2026), $115.0 million (Q1 2026), and $81.0 million (Q4 2025), per Business Quant data.